After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Welcome to the Money blog, Sky News' personal finance and consumer hub. Today: we sample 13 decaf teas in Our Verdict - and ...

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

Pound and bonds recovering after Reeves gets backing, NS&I issue new Junior ISA rate - Stock markets updates and business ...

Compared to the aggregate P/E ratio of 27.38 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of ...